Synergistic Approach of Antibody‐Photosensitizer Conjugate Independent of KRAS‐Mutation and Its Downstream Blockade Pathway in Colorectal Cancer
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202302374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Minji Ahn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical-Chemical Engineering, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 14662, Republic of …. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: the Ministry of Science and ICT, the Ministry of Health & Welfare, the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science and ICT (MSIT).
Abstract (Originalsprache)
Here, a novel approach is presented to improve the efficacy of antibody‐drug conjugates (ADC) by integrating antibody‐mediated immunotherapy and photodynamic therapy (PDT) in a combination therapy system utilizing an antibody‐photosensitizer conjugate (APC) platform based on a poloxamer polymer linker. To specifically target Kirsten rat sarcoma 2 viral oncogene homolog (KRAS)‐mutated cancer cells, an antibody antiepidermal growth factor receptor (EGFR), cetuximab, with a poloxamer linker coupled with the photosensitizer chlorin e6 through click chemistry (cetuximab‐maleimide‐poly(ethylene oxide)‐poly(propylene oxide)‐poly(ethylene oxide)‐chlorine e6 conjugate, CMPXC) is synthesized. CMPXC is cytotoxic upon laser treatment, achieving a 90% cell death by suppressing KRAS downstream signaling pathways associated with ERK and AKT proteins, confirmed using RNA sequencing analysis. In KRAS‐mutated colorectal cancer mouse models, CMPXC significantly enhances antitumor efficacy compared with cetuximab treatment alone, resulting in an 86% reduction in tumor growth. Furthermore, CMPXC treatment leads to a 2.24‐ and 1.75‐fold increase in dendritic and priming cytotoxic T cells, respectively, highlighting the immune‐activating potential of this approach. The findings suggest that the APC platform addresses the challenges associated with ADC development and EGFR‐targeted therapy, including the synergistic advantages of antibody‐mediated immunotherapy and PDT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical-Chemical Engineering, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 14662, Republic of Korea.
- Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 14662, Republic of Korea.
- Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
ORCID-Profile: Kun Na
Förderung
- the Ministry of Science and ICT, the Ministry of Health & Welfare
- the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science and ICT (MSIT)
Zitieren
APA
Ahn, M., Lee, T., Kim, K. S., Lee, S., & Na, K. (2023). Synergistic Approach of Antibody‐Photosensitizer Conjugate Independent of KRAS‐Mutation and Its Downstream Blockade Pathway in Colorectal Cancer. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202302374
Vancouver
Ahn M, Lee T, Kim KS, Lee S, Na K. Synergistic Approach of Antibody‐Photosensitizer Conjugate Independent of KRAS‐Mutation and Its Downstream Blockade Pathway in Colorectal Cancer. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202302374
BibTeX
@article{Ahn2023,
author = {Ahn, Minji and Lee, Taebum and Kim, Kyoung Sub and Lee, Sanghee and Na, Kun},
title = {Synergistic Approach of Antibody‐Photosensitizer Conjugate Independent of KRAS‐Mutation and Its Downstream Blockade Pathway in Colorectal Cancer},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202302374}
}
EUVIMED